Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etretinate-induced skeletal muscle damage.

E Hodak, M David, N Gadoth

    The British Journal of Dermatology
    |May 1, 1987
    PubMed
    Summary

    Etretinate, a medication for skin conditions like psoriasis, can cause reversible skeletal muscle damage. Symptoms included muscle pain and weakness, which resolved after discontinuing the drug.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The association between atopic dermatitis and inflammatory bowel disease in adults: A cross-sectional study in a specialized atopic dermatitis clinic.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2023
    Same author

    Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis - a case series.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2022
    Same author

    Paediatric mycosis fungoides - characteristics, management and outcomes with particular focus on the folliculotropic variant.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2022
    Same author

    Paediatric mycosis fungoides - characteristics, management and outcomes with particular focus on the folliculotropic variant.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2022
    Same author

    Percutaneous ethanol sclerotherapy is a promising treatment for recalcitrant angiolymphoid hyperplasia with eosinophilia.

    Clinical and experimental dermatology·2021
    Same author

    Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.

    The British journal of dermatology·2021

    Area of Science:

    • Dermatology
    • Neurology
    • Toxicology

    Background:

    • Etretinate is a retinoid used to treat severe skin conditions such as psoriasis vulgaris and exfoliative dermatitis.
    • Understanding the potential adverse effects of long-term dermatological treatments is crucial for patient safety.

    Observation:

    • Three patients undergoing etretinate therapy presented with symptoms suggestive of muscle damage.
    • Clinical and electromyographic evaluations revealed significant neuromuscular impairment during treatment.

    Findings:

    • One patient exhibited histological evidence of segmental muscle necrosis, confirming drug-induced myopathy.
    • Discontinuation of etretinate resulted in complete clinical recovery and normalization of muscle enzyme levels and electromyogram (EMG) findings.

    Implications:

    • This report highlights the potential for etretinate to cause reversible skeletal muscle damage.
    • Clinicians should monitor patients for signs of myopathy during etretinate treatment and consider drug cessation if symptoms arise.

    Related Experiment Videos